Sage therapeutics, inc. (SAGE)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash flows from operating activities
Net loss

-643,572

-680,238

-669,973

-612,933

-461,690

-372,882

-283,916

-234,717

-287,940

-270,120

-256,599

-220,676

-185,222

-158,987

-131,648

-117,887

-108,167

-94,495

-78,294

-63,727

-44,892

-33,811

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

140,225

153,231

154,192

136,001

130,262

101,963

80,568

64,821

45,143

35,534

35,382

30,399

25,514

23,020

17,013

16,672

17,605

15,240

12,480

8,764

3,701

2,512

0

0

0

Non-cash licensing and consulting fees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,211

1,211

1,211

424

127

0

0

0

Premium on marketable securities

3,175

3,674

2,702

2,027

950

215

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of discount on marketable securities

4,662

6,966

9,420

10,711

10,866

9,892

7,137

4,452

1,674

293

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation

2,600

2,300

1,900

1,527

1,253

1,100

904

733

617

500

478

425

370

281

231

177

134

115

99

83

62

51

0

0

0

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

5,197

4,781

11,685

-4,527

8,477

15,462

13,606

26,125

5,095

1,127

1,474

3,381

3,553

3,362

813

-1,464

1,736

681

1,541

2,499

797

715

0

0

0

Other long-term assets

2,316

3,793

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use operating asset

-7,004

-8,168

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities, current

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities, non-current

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-5,583

-18,783

-1,041

3,641

4,914

24,544

-7,284

2,172

73

-3,693

7,901

87

3,952

7,796

1,898

771

1,448

2,590

1,255

3,586

1,255

441

0

0

0

Accrued expenses and other liabilities

6,605

33,804

28,417

18,345

14,398

10,130

12,889

14,020

6,316

19,996

20,158

14,497

12,923

13,044

10,876

7,321

6,419

5,339

3,559

3,380

4,215

4,353

0

0

0

Net cash used in operating activities

-515,463

-528,706

-513,758

-465,243

-332,034

-260,671

-217,792

-183,697

-242,638

-219,277

-194,154

-178,858

-146,453

-118,678

-103,019

-91,738

-83,510

-70,681

-61,231

-49,202

-36,032

-27,042

0

0

0

Proceeds from sales and maturities of marketable securities

1,139,204

1,171,270

1,208,465

1,299,949

1,200,060

974,757

770,921

414,249

292,432

261,225

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of marketable securities

796,410

1,308,675

1,289,101

1,589,254

1,671,165

1,484,358

1,423,546

1,023,818

619,604

244,403

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of property and equipment

4,770

5,751

6,186

5,244

3,465

2,860

2,856

2,093

1,767

1,360

1,076

907

1,325

1,421

939

852

429

198

205

304

235

128

0

0

0

Net cash provided by (used in) investing activities

338,024

-143,156

-86,822

-294,549

-474,570

-512,461

-655,481

-611,662

-328,939

15,462

2,126

-69,465

-198,074

-230,015

-112,115

-84,374

-429

-198

-205

-304

-235

-128

0

0

0

Cash flows from financing activities
Proceeds from stock option exercises and employee stock purchase plan issuances

36,329

48,850

48,312

40,988

32,032

29,108

36,454

32,063

28,176

15,972

7,676

4,405

1,657

1,406

795

606

885

730

0

0

0

-

-

-

-

Payment of employee tax obligations related to vesting of restricted stock units

-

2,175

2,175

692

692

904

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments of offering costs

-

328

328

328

175

340

0

0

0

-

-

-

-

599

635

725

1,148

584

0

0

0

-

-

-

-

Proceeds from public offerings of common stock, net of commissions and underwriting discounts

-

561,277

561,277

561,277

561,277

631,494

0

0

0

-

-

-

-

330,175

0

0

0

-

-

-

-

96,255

0

0

0

Net cash provided by financing activities

34,588

607,624

607,086

601,245

592,442

659,358

992,550

988,159

984,377

341,818

7,676

193,580

190,832

330,982

330,335

140,881

270,457

129,866

129,586

224,613

94,004

146,870

0

0

0

Net increase in cash, cash equivalents and restricted cash

-142,851

-64,238

6,506

-158,547

-214,162

-113,774

119,277

192,800

412,800

138,003

-184,352

-54,743

-153,695

-17,711

115,201

-35,231

186,518

58,987

68,150

175,107

57,737

119,700

0

0

0

Supplemental disclosure of non-cash operating and investing activities
Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,294

0

0

0

Purchases of property and equipment included in accounts payable

2

65

43

293

114

51

0

0

0

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

Public offering costs included in accounts payable

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

165

0

0

0

-

-

-

-

Deferred public offering costs included in accounts payable or accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0